Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antiviral_drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AX25
|
| gptkbp:CASNumber |
1985606-14-1
|
| gptkbp:chemicalFormula |
C27H23F2N3O7
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:developer |
gptkb:Shionogi
|
| gptkbp:eliminationHalfLife |
79.1 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:form |
gptkb:tablet
granules |
| gptkbp:genericName |
gptkb:baloxavir_marboxil
|
| gptkbp:indication |
post-exposure prophylaxis of influenza
treatment of acute uncomplicated influenza |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Roche
|
| gptkbp:mechanismOfAction |
cap-dependent endonuclease inhibitor
|
| gptkbp:metabolism |
liver (UGT1A3, CYP3A4)
|
| gptkbp:pregnancyCategory |
not assigned (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:sinusitis
bronchitis nausea diarrhea headache |
| gptkbp:usedFor |
gptkb:influenza
|
| gptkbp:bfsParent |
gptkb:Roche
|
| gptkbp:bfsLayer |
6
|
| http://www.w3.org/2000/01/rdf-schema#label |
Xofluza
|